ZA201601443B - Administration of kynurenine depleting enzymes for tumor therapy - Google Patents
Administration of kynurenine depleting enzymes for tumor therapyInfo
- Publication number
- ZA201601443B ZA201601443B ZA2016/01443A ZA201601443A ZA201601443B ZA 201601443 B ZA201601443 B ZA 201601443B ZA 2016/01443 A ZA2016/01443 A ZA 2016/01443A ZA 201601443 A ZA201601443 A ZA 201601443A ZA 201601443 B ZA201601443 B ZA 201601443B
- Authority
- ZA
- South Africa
- Prior art keywords
- administration
- tumor therapy
- depleting enzymes
- kynurenine
- kynurenine depleting
- Prior art date
Links
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 title 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000000779 depleting effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y307/00—Hydrolases acting on carbon-carbon bonds (3.7)
- C12Y307/01—Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
- C12Y307/01003—Kynureninase (3.7.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361872132P | 2013-08-30 | 2013-08-30 | |
| US201461986366P | 2014-04-30 | 2014-04-30 | |
| PCT/US2014/053437 WO2015031771A2 (en) | 2013-08-30 | 2014-08-29 | Administration of kynurenine depleting enzymes for tumor therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201601443B true ZA201601443B (en) | 2019-08-28 |
Family
ID=52583559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2016/01443A ZA201601443B (en) | 2013-08-30 | 2016-03-02 | Administration of kynurenine depleting enzymes for tumor therapy |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9808486B2 (https=) |
| EP (2) | EP3492094A1 (https=) |
| JP (4) | JP6307163B2 (https=) |
| KR (2) | KR102271498B1 (https=) |
| CN (2) | CN105722522B (https=) |
| AU (1) | AU2014312119B2 (https=) |
| BR (1) | BR112016004095A2 (https=) |
| CA (2) | CA3173052A1 (https=) |
| ES (1) | ES2707711T3 (https=) |
| IL (2) | IL244312B (https=) |
| WO (1) | WO2015031771A2 (https=) |
| ZA (1) | ZA201601443B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| KR102271498B1 (ko) | 2013-08-30 | 2021-07-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 종양 치료를 위한 키누레닌 고갈 효소의 투여 |
| JP7080053B2 (ja) * | 2014-08-29 | 2022-06-03 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| ES2753391T3 (es) | 2014-10-14 | 2020-04-08 | Halozyme Inc | Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas |
| CA2984624A1 (en) * | 2015-03-18 | 2016-09-22 | Baylor College Of Medicine | Her2/erbb2 chimeric antigen receptor |
| WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| US11542486B2 (en) | 2016-03-02 | 2023-01-03 | Board Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| BR112019006652A2 (pt) | 2016-10-13 | 2019-07-02 | Juno Therapeutics Inc | métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| CN111246865A (zh) * | 2017-07-12 | 2020-06-05 | 同生运营公司 | 程序化以在肿瘤细胞中产生免疫调节剂和抗癌治疗剂的微生物 |
| WO2019089740A1 (en) * | 2017-11-03 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| CA3096549A1 (en) | 2018-04-16 | 2019-10-24 | Board Of Regents, The University Of Texas System | Human kynureninase enzymes and uses thereof |
| CN110412179A (zh) * | 2018-04-26 | 2019-11-05 | 缪荣明 | 一种液相色谱检测颗粒酶a的方法 |
| EP3893923A2 (en) * | 2018-12-14 | 2021-10-20 | Autolus Limited | Cell |
| CA3154817A1 (en) * | 2019-10-17 | 2021-04-22 | James Nolan | Pegylated kynureninase enzymes and uses thereof for the treatment of cancer |
| AU2021217003A1 (en) | 2020-02-04 | 2022-09-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-dinitrophenol chimeric antigen receptors |
| JPWO2023229024A1 (https=) * | 2022-05-27 | 2023-11-30 | ||
| WO2024085280A1 (ko) * | 2022-10-20 | 2024-04-25 | 서울대학교 산학협력단 | 신규한 키뉴레니나제 및 이의 용도 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20030194721A1 (en) | 2001-09-19 | 2003-10-16 | Incyte Genomics, Inc. | Genes expressed in treated foam cells |
| WO2003065984A2 (en) | 2002-02-01 | 2003-08-14 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cardiovascular disease |
| CN1330774C (zh) * | 2002-03-01 | 2007-08-08 | 国家人类基因组南方研究中心 | 犬尿氨酸水解酶多态性及其用途 |
| WO2004094409A1 (en) | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| JP2008237022A (ja) | 2005-06-30 | 2008-10-09 | Osaka Prefecture | 非小細胞肺がんの予防・治療剤および診断薬 |
| ES2444574T3 (es) * | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| GB0625310D0 (en) * | 2006-12-19 | 2007-01-24 | Bioalvo | Yeast platform construction and screening methods |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20120085209A (ko) * | 2011-01-21 | 2012-07-31 | 인제대학교 산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| WO2012099441A2 (ko) | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| EP2753315B1 (en) * | 2011-09-07 | 2017-03-01 | Deutsches Krebsforschungszentrum | Means and methods for treating and/or preventing natural ahr ligand-dependent cancer |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| KR102271498B1 (ko) * | 2013-08-30 | 2021-07-05 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 종양 치료를 위한 키누레닌 고갈 효소의 투여 |
| JP7080053B2 (ja) | 2014-08-29 | 2022-06-03 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| US11542486B2 (en) | 2016-03-02 | 2023-01-03 | Board Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| JP6912171B2 (ja) * | 2016-09-15 | 2021-07-28 | 株式会社トプコン | 眼科検査装置 |
| CA3096549A1 (en) | 2018-04-16 | 2019-10-24 | Board Of Regents, The University Of Texas System | Human kynureninase enzymes and uses thereof |
-
2014
- 2014-08-29 KR KR1020167008486A patent/KR102271498B1/ko active Active
- 2014-08-29 AU AU2014312119A patent/AU2014312119B2/en active Active
- 2014-08-29 ES ES14840339T patent/ES2707711T3/es active Active
- 2014-08-29 EP EP18204264.8A patent/EP3492094A1/en not_active Withdrawn
- 2014-08-29 KR KR1020217019661A patent/KR102442231B1/ko active Active
- 2014-08-29 CA CA3173052A patent/CA3173052A1/en active Pending
- 2014-08-29 JP JP2016537898A patent/JP6307163B2/ja active Active
- 2014-08-29 WO PCT/US2014/053437 patent/WO2015031771A2/en not_active Ceased
- 2014-08-29 CN CN201480053899.1A patent/CN105722522B/zh active Active
- 2014-08-29 CN CN202111132607.1A patent/CN113957061A/zh active Pending
- 2014-08-29 US US14/473,040 patent/US9808486B2/en active Active
- 2014-08-29 CA CA2922670A patent/CA2922670C/en active Active
- 2014-08-29 BR BR112016004095A patent/BR112016004095A2/pt not_active Application Discontinuation
- 2014-08-29 EP EP14840339.7A patent/EP3038636B1/en active Active
-
2016
- 2016-02-28 IL IL244312A patent/IL244312B/en active IP Right Grant
- 2016-03-02 ZA ZA2016/01443A patent/ZA201601443B/en unknown
- 2016-11-14 US US15/351,060 patent/US20170056449A1/en not_active Abandoned
-
2018
- 2018-03-09 JP JP2018042760A patent/JP7029316B2/ja active Active
-
2019
- 2019-02-19 IL IL264901A patent/IL264901B/en active IP Right Grant
- 2019-04-02 US US16/373,588 patent/US10772913B2/en active Active
-
2020
- 2020-04-16 JP JP2020073212A patent/JP2020111611A/ja not_active Withdrawn
- 2020-08-18 US US16/996,806 patent/US11534463B2/en active Active
-
2022
- 2022-08-23 JP JP2022132161A patent/JP2022159570A/ja active Pending
- 2022-12-13 US US18/065,451 patent/US20240091258A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201601443B (en) | Administration of kynurenine depleting enzymes for tumor therapy | |
| IL287516A (en) | Medicinal uses of empagliflozin | |
| IL241101B (en) | Medicinal uses of empagliflozin | |
| IL237138A0 (en) | Methods of administration of pirfenidone therapy | |
| IL241102B (en) | Medicinal uses of empagliflozin | |
| IL250833A0 (en) | Administering enzymes to reduce the level of kynurenine in the treatment of tumors | |
| IL236678B (en) | Crystallin-alpha inhibitors for the treatment of cataracts | |
| PT2879672T (pt) | Terapia combinada para o tratamento da esclerose múltipla | |
| IL240987A0 (en) | Methods for treating solid tumors in children | |
| PT2804599T (pt) | Terapêutica de associação para o tratamento de cancro | |
| SI2981271T1 (sl) | Terapevtske uporabe empagliflozina | |
| SG11201405766SA (en) | Methods for increasing efficacy of cd37-based therapy | |
| PL3598971T3 (pl) | Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny | |
| EP2996716A4 (en) | Correlates of efficacy relating to tumor vaccines | |
| IL244620A0 (en) | A drug combination including laquinimod for the treatment of multiple sclerosis | |
| HK1225291A1 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| GB201322036D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201310488D0 (en) | New therapeutic uses of enzyme inhibitors | |
| IL233495A0 (en) | Combination for cancer treatment | |
| AU2013902004A0 (en) | Compositions for Therapy and Methods of Treatment |